Abbott said that the Japanese Red Cross Society selected it as the exclusive supplier of blood and plasma screening serological instrumentation, tests, and consumables.
The financing will go toward continued development of its MultiPath technology to rapidly identify hospital infections and determine their antibiotic susceptibility.
AllerGenis has the non-exclusive right to use the xMAP technology to develop, market, and sell a precision food allergy diagnostic assay.
GenMark got clearance for an assay to detect fungal pathogens from blood cultures of patients with suspected bloodstream infections, and it received clearance for a bacterial assay.
The decision makes OVA1 available to Cigna's 15 million covered customers and brings the total number of lives covered for the test to 167 million.
QuantiFeron-TB Gold Plus features antigens that measure the cell-mediated immune response to TB infection from both CD4 and CD8 T cells.
The company will provide 1 million rapid diagnostic tests, $750,000, and technical expertise as part of an effort in Odisha to eliminate the disease.
Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.
Abbott CEO Miles White is bullish on the firm's Alinity systems, while Quest and LabCorp see acquisitions as the likely result of further PAMA-related cuts.
At JP Morgan, Qiagen CEO Peer Schatz discussed a new digital PCR system and handheld reader for TB testing; Qiagen's acquisition of N-of-One; and its new sample prep system.
In a recent study, researchers found that a PSA SNP variant affected protein stability, activity, and glycosylation, and could impact clinical measurements.
Siemens Healthineers CEO Bernd Montag talked about the positive impact the firm's Attelica system is having on its revenues, while Bruker discussed plans for the BioTyper platform and assays in the pipeline.
The company also reaffirmed fiscal fourth quarter growth expectations including double-digit growth in the US for its TB testing products.
Worcester Polytechnic Institute researchers are developing an inexpensive handheld platform that could provide C. difficile test results in minutes.
A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.
The company plans to launch on the platform tests for diagnosing sexually transmitted diseases and for distinguishing between viral and bacterial infections.
The test is the first quantitative test on the firm's flagship Sofia immunoassay platform.
The firm anticipates deploying funds to complete the integration of Biosensia, a developer of multi-analyte assays on a CLIA-waived testing platform.
The company also received US Food and Drug Administration for its specific immunoglobulin E test for dust mite allergen that runs on the system.
The firm has added two new targets to make the Sofia 2 POC Lyme+ Fluorescent Immunoassay more relevant to Lyme disease pathogens in Europe.